The city of Ocala, Florida, currently has 5 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
A Study Evaluating the Safety and Efficacy of AP01 in Participants With Progressive Pulmonary Fibrosis (PPF)
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Renstar Medical Research, Ocala, Florida
Conditions: Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/19/2024
Locations: Local Institution - 0220, Ocala, Florida
Conditions: Progressive Pulmonary Fibrosis
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/17/2024
Locations: Renstar Medical Research, Ocala, Florida
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/01/2024
Locations: Renstar Medical Research, Ocala, Florida
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: Renstar Medical Research, Ocala, Florida
Conditions: Idiopathic Pulmonary Fibrosis